Healthcare Resource Utilization and Survival of Patients With HR+/HER2-negative Metastatic Breast Cancer After Treatment With CDK4/6-Inhibitors in Finland
Author(s)
Peeter Karihtala, MD1, Samuli Tuominen, MSc2, Trude Ågesen, PhD3, Greta Bütepage, MSc4, Maria Polyzoi, MSc4, Mariann Lassenius, PhD5.
1Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland, 2Medaffcon, Helsinki, Finland, 3AstraZeneca, Oslo, Norway, 4AstraZeneca, Stockholm, Sweden, 5Medaffcon Oy, Espoo, Finland.
1Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland, 2Medaffcon, Helsinki, Finland, 3AstraZeneca, Oslo, Norway, 4AstraZeneca, Stockholm, Sweden, 5Medaffcon Oy, Espoo, Finland.
OBJECTIVES: In recent years the treatment landscape for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) has rapidly evolved. The aim of this study was to describe the population of HR+/HER2- mBC patients treated with CDK4/6-inhibitors in first line (1L) followed by any second line (2L) treatment, and to estimate the health care resource utilisation (HCRU) and real-world overall survival (rwOS).
METHODS: This observational study included patients with HR+/HER2- mBC from the Helsinki and Uusimaa region, representative of approximately 30% of the Finnish BC-population. The study population included patients diagnosed with confirmed HR+/HER2-negative mBC, who had CDK4/6-inhibitors in 1L from January 2017 to June 2023. HCRU included healthcare contacts and costs per patient year. RwOS was estimated from the time of 2L treatment initiation.
RESULTS: In total, 356 patients with HR+/HER2- mBC initiated 1L treatment with a CDK4/6-inhibitor during the study period. The three-year probability for continued 1L treatment was 40.5% (95% CI: 35.1-46.8) and for 2L treatment initiation was 48.6% (95% CI: 43.0-54.8), which included chemotherapy and endocrine therapy (ET). The median age at 2L treatment initiation was 67 years (66 years; chemotherapy, 75 years; ET). Most mBC-related HCRU contacts and costs in both 1L and 2L came from the outpatient setting. 2L chemotherapy-treated patients incurred approximately twice the costs of 2L ET-treated patients. For 1L CDK4/6i-treated patients, the 2-year rwOS estimates from 2L treatment initiation were 40.1% and 42.8% for 2L chemotherapy and 2L ET, respectively.
CONCLUSIONS: The increased HCRU in 2L chemotherapy-treated patients could be due to the worse safety profile and often more demanding treatment administrations. Together with the slightly worse rwOS outcomes, it may indicate that patients receiving chemotherapy have a potentially more severe disease and an increased need for medical care.
METHODS: This observational study included patients with HR+/HER2- mBC from the Helsinki and Uusimaa region, representative of approximately 30% of the Finnish BC-population. The study population included patients diagnosed with confirmed HR+/HER2-negative mBC, who had CDK4/6-inhibitors in 1L from January 2017 to June 2023. HCRU included healthcare contacts and costs per patient year. RwOS was estimated from the time of 2L treatment initiation.
RESULTS: In total, 356 patients with HR+/HER2- mBC initiated 1L treatment with a CDK4/6-inhibitor during the study period. The three-year probability for continued 1L treatment was 40.5% (95% CI: 35.1-46.8) and for 2L treatment initiation was 48.6% (95% CI: 43.0-54.8), which included chemotherapy and endocrine therapy (ET). The median age at 2L treatment initiation was 67 years (66 years; chemotherapy, 75 years; ET). Most mBC-related HCRU contacts and costs in both 1L and 2L came from the outpatient setting. 2L chemotherapy-treated patients incurred approximately twice the costs of 2L ET-treated patients. For 1L CDK4/6i-treated patients, the 2-year rwOS estimates from 2L treatment initiation were 40.1% and 42.8% for 2L chemotherapy and 2L ET, respectively.
CONCLUSIONS: The increased HCRU in 2L chemotherapy-treated patients could be due to the worse safety profile and often more demanding treatment administrations. Together with the slightly worse rwOS outcomes, it may indicate that patients receiving chemotherapy have a potentially more severe disease and an increased need for medical care.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EPH123
Topic
Clinical Outcomes, Economic Evaluation, Epidemiology & Public Health
Topic Subcategory
Disease Classification & Coding
Disease
Oncology